The Chemours Company (NYSE:CC) Shares Bought by Barclays PLC

Barclays PLC grew its stake in The Chemours Company (NYSE:CC - Free Report) by 41.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 152,433 shares of the specialty chemicals company's stock after acquiring an additional 44,884 shares during the quarter. Barclays PLC owned about 0.10% of Chemours worth $2,576,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC lifted its holdings in Chemours by 99.7% in the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after acquiring an additional 765 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in Chemours by 100.4% during the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 1,119 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in shares of Chemours in the 4th quarter valued at approximately $48,000. KBC Group NV increased its position in shares of Chemours by 38.2% in the 4th quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock valued at $104,000 after purchasing an additional 1,708 shares during the last quarter. Finally, Sterling Capital Management LLC raised its holdings in shares of Chemours by 54.8% in the 4th quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock valued at $143,000 after purchasing an additional 2,991 shares in the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Stock Performance

Shares of Chemours stock opened at $12.36 on Thursday. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of 21.68 and a beta of 1.84. The Chemours Company has a 12 month low of $9.33 and a 12 month high of $29.21. The firm's fifty day simple moving average is $13.02 and its 200-day simple moving average is $16.91. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company had revenue of $1.36 billion for the quarter, compared to analysts' expectations of $1.37 billion. As a group, equities analysts forecast that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were issued a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, February 28th. This represents a $1.00 annualized dividend and a yield of 8.09%. Chemours's dividend payout ratio is currently 175.44%.

Wall Street Analyst Weigh In

CC has been the topic of several recent analyst reports. The Goldman Sachs Group dropped their target price on Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a report on Tuesday, January 7th. Barclays cut their target price on Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 1st. Morgan Stanley lowered their price target on Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Truist Financial cut their price objective on shares of Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, BMO Capital Markets lowered their target price on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $21.56.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.